Your session is about to expire
← Back to Search
Electrical Stimulation
Electrical Stimulation for Glaucoma
Phase 1 & 2
Waitlist Available
Led By Jeffrey L Goldberg, MD PhD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Participant must be at least 18.
Participant's clinical diagnosis must be consistent with normal tension glaucoma characterized by specific features on reliable Humphrey Visual Field 24-2 testing.
Must not have
Participant is unable to comply with study procedures or follow-up visits.
Participant has a requirement of acyclovir and/or related products during study duration.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Summary
This trial aims to test how well a treatment called transorbital alternating current stimulation (rtACS) using the EYETRONIC device works for patients with glaucoma.
Who is the study for?
This trial is for individuals with open-angle glaucoma, a common eye condition that can lead to vision loss. Specific eligibility criteria are not provided, but typically participants would need to meet certain health standards and not have conditions that could interfere with the study.
What is being tested?
The trial is testing the effectiveness of a treatment called transorbital alternating current stimulation (rtACS) using a device named EYETRONIC. It's compared against a sham rtACS, which is like a placebo where no actual stimulation is given.
What are the potential side effects?
Potential side effects are not detailed in the information provided. However, similar electrical stimulation treatments may cause discomfort or temporary visual disturbances.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
I have been diagnosed with normal tension glaucoma based on specific visual field testing results.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I can follow the study's procedures and attend all visits.
Select...
I need to take acyclovir or similar drugs during the study.
Select...
I have a specific eye condition.
Select...
I am currently taking steroids or other medications that suppress my immune system.
Select...
I do not have any specific medical devices or conditions that would exclude me.
Select...
I do not have uncontrolled high blood pressure, epilepsy, drug/alcohol abuse issues, and I am not comatose.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Mean Deviation (MD)
Pointwise Linear Regression (PLR)
Visual Field Index (VFI)
Secondary study objectives
Best Corrected Visual Acuity
Ganglion Cell Layer
OCT-Angiography
+4 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: rtACS treatmentExperimental Treatment1 Intervention
Participants will receive 10 days of rtACS treatment in office.
Group II: ShamPlacebo Group1 Intervention
Participants will be wearing device but no stimulation will occur for 10 treatments in office.
Find a Location
Who is running the clinical trial?
Stanford UniversityLead Sponsor
2,491 Previous Clinical Trials
17,519,182 Total Patients Enrolled
13 Trials studying Glaucoma
623 Patients Enrolled for Glaucoma
Neuromodtronic, GmbHUNKNOWN
Jeffrey L Goldberg, MD PhDPrincipal InvestigatorStanford University
3 Previous Clinical Trials
125 Total Patients Enrolled
3 Trials studying Glaucoma
125 Patients Enrolled for Glaucoma